Werewolf Therapeutics (HOWL)

• Market cap: $67.7M
• 1 day: 5.71%
• 5 days: 3.5%
• 1 month: 11.28%
• 3 months: 19.35%
• 6 months: 27.59%
• Year to date: -5.13%
• 1 year: -33.33%
• 5 years: -90.81%
• 10 years: -90.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.

Employees: 46

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

7% less funds holding

Funds holding: 70 [Q1] → 65 (-5) [Q2]

9% less capital invested

Capital invested by funds: $26.7M [Q1] → $24.3M (-$2.33M) [Q2]

11.45% less ownership

Funds ownership: 61.22% [Q1] → 49.78% (-11.45%) [Q2]

21% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 19

23% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 22

89% less call options, than puts

Call options by funds: $1K | Put options by funds: $9K

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3
• Avg. target: $5.5
• High target: $8

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

B of A Securities Jason Zemansky	$8	Buy Maintained	25 Aug 2025
JMP Securities Reni J. Benjamin	$3	Market Outperform Maintained	21 Aug 2025